Ferris et al. uncovered the mechanism of pevonedistat in inducting cell death for colorectal cancer (CRC) therapy, and the responses were effective for both p53 wild-type and mutant mCRC, implying the applicable potent of pevonedistat in other cancers [38]. Here, TP53 is linked to colorectal cancer.